Jay Stewart, MD
Ophthalmology · San Francisco, CANPI 1134183189
Payments from drug & device makers
What this record shows
The money is spread across several categories — royalties or licence payments (43.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Merck at 46.6% of the total. Reporting peaked in 2022 at $95,389 and has fallen 96.6% since, to $3,230 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 66 payments — averaging $3315.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$102K
- Carl Zeiss Meditec, Inc.$84K
- F. Hoffmann-la Roche AG$15K
- Genentech, Inc.$13K
- ANI Pharmaceuticals, Inc.$3K
- Genentech USA, Inc.$683
- plus $2K from 9 others
Across 12 payments — averaging $21,533 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$202K
- Genentech, Inc.$32K
- F. Hoffmann-la Roche AG$24K
What the payments were for
- Royalty or licence$95,20043%
- Consulting fees$92,15942%
- Speaking & faculty fees$12,9626%
- Travel & lodging$16,5308%
- Food & beverage$1,9851%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $102,004 |
| Carl Zeiss Meditec, Inc. | 19 | $83,597 |
| F. Hoffmann-la Roche AG | 11 | $15,166 |
| Genentech, Inc. | 8 | $13,214 |
| ANI Pharmaceuticals, Inc. | 2 | $2,580 |
| Genentech USA, Inc. | 5 | $683 |
| Boehringer Ingelheim International GmbH | 1 | $650 |
| Alcon | 5 | $464 |
| Regeneron Healthcare Solutions, Inc. | 1 | $127 |
| Regeneron | 1 | $82 |
| Alimera Sciences, Inc. | 1 | $81 |
| Novartis | 1 | $79 |
| Carl Zeiss Meditec USA, Inc. | 3 | $75 |
| Eyepoint US, Inc. | 1 | $35 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IOLMaster 700$53,150
- ARTEVO 800$31,926
- Humphrey HFA$25,850
- FORUM$22,100
- FORUM Glaucoma Workplace$22,100
- Non-Covered Product$16,458
- CIRRUS HD-OCT$8,950
- VisuMax$8,950
- Lucentis$8,861
- Cataract Suite$5,200
- VERACITY SURGICAL$3,750
- YUTIQ$2,550
- Constellation$417
- VABYSMO$134
- EYLEA HD$127
How this compares
$218,855 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 66 | $3,207 |
| Brimonidine Tartrate | 51 | $2,998 |
| Ketorolac Tromethamine | 53 | $1,732 |
| Atropine Sulfate | 34 | $1,647 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 12 | $869 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $722 |
| Latanoprost | 63 | $557 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 42 | $259 |
| Dorzolamide Hcl | 17 | $241 |
| Timolol Maleate | 18 | $101 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Francisco
- Daniel SchwartzSan Francisco$8M
- Gaurav ShahSan Francisco$620K
- Shan LinSan Francisco$374K
- H TanakaSan Francisco$238K
- Scott SoSan Francisco$173K
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.